Advancing Alzheimer’s diagnostics: Why inclusive science is key to health equity
:quality(90)/)
Part of seriesDiagnostic innovation starts here
Medical research has long struggled with a critical diversity gap, relying on clinical trial cohorts heavily skewed toward Western demographics. In Alzheimer’s disease, where Black, Hispanic, and Asian communities face disproportionate burdens yet lower rates of timely diagnosis, this lack of representation has profound consequences.
While systemic healthcare barriers drive much of this diagnostic delay, the issue is compounded by a scientific blind spot: emerging diagnostic tools are rarely validated across racially and ethnically diverse cohorts. Without establishing equitable diagnostic cutoffs across all demographic groups, next-generation diagnostics risk reinforcing, rather than closing, disparities in global patient care.1
With capabilities spanning both diagnostics and pharmaceuticals, Roche aims to identify neurodegenerative disease earlier and accelerate patient access to targeted care. To ensure these breakthroughs truly benefit the diverse communities we serve, scientific innovation must be matched by clinical research that authentically reflects global patient populations.
Recent multi-centre studies in Chinese and Korean populations validating Roche’s blood-based Alzheimer’s biomarkers demonstrate how inclusive research ensures diagnostic tools perform equitably across diverse ethnic groups, helping broaden access to scalable, early detection.1,2,3
Translating science across diverse cohorts
Phosphorylated tau (pTau) proteins serve as vital indicators of underlying Alzheimer’s pathology in the brain. When measured in the blood, they offer a scalable, minimally invasive tool to help clinicians identify disease pathology earlier and more accurately.
To interpret these biomarker measurements, clinicians rely on validated diagnostic cutoffs that classify whether an individual has a low, intermediate, or high likelihood of amyloid pathology, the hallmark presence of toxic protein plaques in the brain.
However, verifying that a standard reference point works reliably across different patient groups requires rigorous validation. Demographic differences, biological variations, and comorbidities like kidney impairment can influence baseline biomarker levels, making diverse representation essential to prove that diagnostic cutoffs deliver equitable, accurate results globally.1,2,3
Two recent studies evaluated Roche’s plasma pTau biomarker cutoffs in Asian populations. Presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference, the research assessed whether global diagnostic benchmarks and cutoffs perform consistently across diverse ethnic groups.
Clinical performance in China: A multi-centre study involving 508 participants in China evaluated how well blood-based pTau217 thresholds matched gold-standard brain scans. Using established global benchmarks, the blood test demonstrated high concordance, achieving between 92% and 96% agreement with imaging for both disease detection and rule-out. This confirmed that universal reference points reliably distinguish amyloid status in this population without requiring local adjustments.2
Clinical performance in South Korea: An analysis of 1,895 participants from the K-ROAD (Korea-Registries to Overcome Dementia and Accelerate Dementia Research) study evaluated the performance of blood-based pTau217 and pTau181 assays against gold-standard brain scans. According to their respective intended uses, both tests exceeded the 90% performance benchmark established by the Global CEO Initiative on Alzheimer’s disease. This demonstrates the strong reliability of established global cut-offs in Asian populations.3,4
True precision in healthcare isn't just about the sensitivity of a biomarker; it’s about proving that diagnostic metrics deliver clarity for every patient, regardless of their background or geography. Validating biomarkers across inclusive clinical cohorts is what turns innovative science into trusted clinical reality.
Democratising access to timely care
Validating scientific tools across diverse populations demonstrates that standardized diagnostic metrics can be applied globally without compromising accuracy.2,3
Inclusive trials support the development of blood-based diagnostic technologies that can reduce result turnaround times to help patients receive timely clarity regardless of geography or demographic background. 1,2,3
These studies show why inclusive research matters beyond the trial itself. By generating evidence across diverse populations, Roche helps ensure diagnostic advances are clinically meaningful for all patients, closing gaps in access and driving better health outcomes across global communities.
References
Alzheimer’s Association, Alzheimer’s Disease Facts and Figures (2026)
Data presented at CTAD 2026. Manuscripts in preparation.
Data presented at CTAD 2026. Manuscripts in preparation.
:quality(90)/)
:quality(90)/)
:quality(90)/)